Published in N Engl J Med on September 11, 2008
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (PENILANE) | NCT02014831
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol (2012) 3.98
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer (2011) 2.41
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol (2014) 2.03
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer (2011) 1.78
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
HPV & head and neck cancer: a descriptive update. Head Neck Oncol (2009) 1.60
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol (2016) 1.51
Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo. ACS Nano (2012) 1.49
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol (2010) 1.41
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J Oncol (2009) 1.38
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One (2009) 1.37
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2012) 1.27
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res (2011) 1.26
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol (2009) 1.24
Molecular therapy in head and neck oncology. Nat Rev Clin Oncol (2009) 1.24
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A (2011) 1.21
AXL mediates resistance to cetuximab therapy. Cancer Res (2014) 1.20
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol (2014) 1.19
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs (2011) 1.17
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol (2009) 1.16
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer (2012) 1.15
Palliative low dose fortnightly methotrexate in oral cancers: Experience at a rural cancer centre from India. South Asian J Cancer (2014) 1.15
Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies. J Dent Res (2014) 1.15
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer (2010) 1.15
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell (2015) 1.14
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev (2010) 1.13
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol (2011) 1.13
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2009) 1.12
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol (2014) 1.11
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol (2013) 1.10
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget (2011) 1.10
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol (2014) 1.09
mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst (2014) 1.09
Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist (2010) 1.08
The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol (2010) 1.07
Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia (2012) 1.07
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Curr Oncol (2013) 1.06
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res (2013) 1.06
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 1.05
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2010) 1.05
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol (2014) 1.05
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol (2011) 1.04
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res (2011) 1.01
Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. Eur Arch Otorhinolaryngol (2009) 1.01
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep (2014) 1.00
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget (2014) 0.99
Radiotherapy and "new" drugs-new side effects? Radiat Oncol (2011) 0.98
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLoS One (2012) 0.98
The road to resistance: EGFR mutation and cetuximab. Nat Med (2012) 0.98
Squamous cell carcinoma of the head and neck in the elderly. Rep Pract Oncol Radiother (2012) 0.98
Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One (2012) 0.97
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res (2009) 0.97
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther (2013) 0.97
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol (2011) 0.97
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res (2009) 0.96
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer (2009) 0.96
Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol (2009) 0.96
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol (2010) 0.95
Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery (2012) 0.95
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol (2013) 0.94
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol (2013) 0.94
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol (2008) 5.78
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol (2006) 5.56
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol (2008) 5.50
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol (2013) 3.36
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol (2007) 3.35
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 3.24
Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06
Global human footprint on the linkage between biodiversity and ecosystem functioning in reef fishes. PLoS Biol (2011) 3.02
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol (2012) 2.86
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol (2008) 2.85
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol (2010) 2.83
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (2004) 2.82
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer (2010) 2.43
Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol (2002) 2.36
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol (2005) 2.30
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2013) 2.14
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol (2009) 2.11
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol (2007) 2.10
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist (2012) 1.96
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance. Leuk Lymphoma (2014) 1.94
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood (2006) 1.85
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score. Spine (Phila Pa 1976) (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol (2013) 1.74
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol (2005) 1.70
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol (2004) 1.69
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst (2012) 1.62
Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol (2012) 1.59
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie (2008) 1.57
Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther (2006) 1.54
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer (2004) 1.54
Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost (2007) 1.52
Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol (2006) 1.51
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49
Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol (2004) 1.47
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol (2011) 1.46
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev (2010) 1.44
Contemporary minimally-invasive extended pelvic lymph node dissection for prostate cancer before curative radiotherapy: prospective standardized analysis of complications. Int J Urol (2014) 1.42
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood (2006) 1.41
Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer. Prostate (2014) 1.41
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol (2014) 1.40
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.40
Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int (2008) 1.39
SEOM guidelines for endometrial cancer. Clin Transl Oncol (2012) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol (2006) 1.36
Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY. Hum Pathol (2005) 1.36
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist (2012) 1.34
Guidelines on testicular cancer. Eur Urol (2005) 1.32
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32
Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res (2009) 1.31
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol (2009) 1.28
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate (2010) 1.28
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res (2010) 1.28
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica (2009) 1.27
Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol (2011) 1.26